VivoSeq
Cardiovascular

Pulmonary Arterial Hypertension (PAH)

4

Pipeline Programs↗

2

Active Trials↗

3

Companies Involved↗

Pulmonary Arterial Hypertension (PAH) is an early-stage landscape with 4 programs across 3 companies. The most active players are Regeneron, Eli Lilly, Pfizer.

Intelligence

Pipeline Metrics

Competitive Density

27/100

Pipeline Velocity

11/100

Mech. Concentration

67/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Regeneron logo

Regeneron

1 program

Phase 2Eli Lilly logo

Eli Lilly

1 program

Phase 2Pfizer logo

Pfizer

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

2

clinical trials

Not yet recruiting1 · 50%
Recruiting1 · 50%

Clinical Trials

Trial Activity

Comparison of the Efficacy and Safety of Dopamine, Norepinephrine and Epinephrine in the Treatment of Pulmonary Hypertensive Crisis Under Hemodynamic Monitoring
Not yet recruiting·CChina National Center for Cardiovascular Diseases·Preclinical·NCT07667829·75 enrolled
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamic Effects of REGN13335, an Anti-PDGF-B Monoclonal Antibody, in Adults With Pulmonary Arterial Hypertension
Recruiting·Regeneron logoRegeneron·Phase 2·NCT07318597·99 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)